StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Free Report) in a research report released on Monday. The firm issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
Brooklyn ImmunoTherapeutics stock traded up $0.11 during trading hours on Monday, reaching $6.01. 425,767 shares of the stock were exchanged, compared to its average volume of 828,208. The stock has a market cap of $353.54 million, a P/E ratio of -2.65 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52-week low of $5.10 and a 52-week high of $8.31. The firm's 50 day moving average is $5.19 and its 200 day moving average is $2.22.
Brooklyn ImmunoTherapeutics Announces Dividend
The firm also recently announced a monthly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, March 14th were paid a dividend of $0.0862 per share. This represents a $1.03 dividend on an annualized basis and a dividend yield of 17.20%. The ex-dividend date of this dividend was Friday, March 14th. Brooklyn ImmunoTherapeutics's dividend payout ratio (DPR) is -38.33%.
About Brooklyn ImmunoTherapeutics
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Featured Stories
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
